News
SINGAPORE - An injectable drug used to treat obesity is now available via prescription from any licensed physician in ...
Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...
5h
Arabian Post on MSNSingapore Welcomes Wegovy® as a New Prescription Weight‑Loss OptionA once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a chronic disease. The product, from Novo Nordisk, is licensed for adults and those ...
Dr Rowan French insists lasting weight loss can only be achieved through a balanced approach to psychology, exercise and ...
JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...
The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...
In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
23h
Zacks Investment Research on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results